Latest News & Features
Americas
Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this. 30 April 2013
Americas
James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin. 30 April 2013
Americas
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges. 30 April 2013
Asia
Therapeutic substances used under the folk medicine practices of what is known as ‘traditional knowledge’ are protected by special provisions under Indian patent law. Archana Shanker and Vidisha Garg explore the pros and cons. 1 April 2013
Americas
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications. 1 April 2013
Asia
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain. 1 April 2013
Asia
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out. 1 April 2013
Americas
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case. 1 April 2013
Americas
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives. 1 April 2013
Europe
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains. 1 April 2013